The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | Targeting driver mutations in MPNs
In this video, Shannon Elf, PhD, University of Utah School of Medicine, Salt Lake City, UT, briefly discusses a session focused on the potential for targeting driver mutations in myeloproliferative neoplasms (MPNs), highlighting the importance of exploring new targets beyond JAK-STAT signaling. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Basically, what we sort of discussed in that session was ways to target these cells without going after JAK-STAT signaling, which we already have good inhibitors for JAK-STAT signaling. So I talked about BCL2 and BCLXL. Linda Resar talked about targeting HMGA1. Andy Dunbar talked about new Type II JAK inhibitors. And so I think what’s going to end up happening is it will be potentially some combination of those...
Basically, what we sort of discussed in that session was ways to target these cells without going after JAK-STAT signaling, which we already have good inhibitors for JAK-STAT signaling. So I talked about BCL2 and BCLXL. Linda Resar talked about targeting HMGA1. Andy Dunbar talked about new Type II JAK inhibitors. And so I think what’s going to end up happening is it will be potentially some combination of those. But I’m so excited that we’re going after new targets because I think for a long time the focus was just JAK-STAT signaling, and now we’ve really, you know, we understand the biology of MPNs better now, and so it’s opened the door for new therapies. So all very exciting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultant for Paragon Therapeutics; Collaboration with Incyte.
